Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma
The Lancet Oncology Aug 11, 2017
Alderson D et al. – Four cycles of neoadjuvant epirubicin, cisplatin, and capecitabine (ECX) compared with two cycles of cisplatin and fluorouracil (CF) did not increase survival,
Methods
- 897 patients with surgically resectable oesophageal adenocarcinoma were recruited; 451 were assigned to the CF group and 446 to the ECX group.
- The primary outcome measure was overall survival.
Results
- The median survival was 23.4 months with CF and 26.1 months (22.5Â29.7) with ECX (HR = 0.90.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
